Benidipine

Benidipine

Benidipine

Antihypertensive drug of the calcium channel blocker class

Benidipine is a dihydropyridine calcium channel blocker for the treatment of high blood pressure (hypertension). It is a triple L-, T-, and N-type calcium channel blocker. It is reno- and cardioprotective.

Quick Facts Clinical data, AHFS/Drugs.com ...

It was patented in 1981 and approved for medical use in 1991.[1]

Dosing

Benidipine is dosed as 2–8 mg once daily.[2]

Mechanism

Benidipine is a calcium channel blocker.

Benidipine has additionally been found to act as an antagonist of the mineralocorticoid receptor, or as an antimineralocorticoid.[3]

Names

Other names include Benidipinum or benidipine hydrochloride.

Benidipine is sold as Coniel by Kyowa Hakko Kogyo.

Benidipine is initially licensed for use in Japan and selected Southeast Asian countries and later in Turkey, where it is sold as 4 mg tablets.

References

  1. [1]
    Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 465. ISBN 9783527607495.
  2. [2]
    Hi-Eisai Pharmaceutical, Inc. "Coniel (benidipine) package insert (Philippines)". MIMS Philippines. CMPMedica. Retrieved 2008-03-31.
  3. [3]
    Luther JM (September 2014). "Is there a new dawn for selective mineralocorticoid receptor antagonism?". Current Opinion in Nephrology and Hypertension. 23 (5): 456–61. doi:10.1097/MNH.0000000000000051. PMC 4248353. PMID 24992570.
Share this article:

This article uses material from the Wikipedia article Benidipine, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.